Security readout for executives and security teams
Plain-English summary
CVE-2020-16247 is a configuration weakness in Philips Clinical Collaboration Platform 12.2.1 and earlier. It may let unintended actors access a resource they should not control. The main business concern is potential disruption, because the published CVSS rates availability impact as high.
Executive priority
Treat as a moderate clinical technology risk. It is not listed as actively exploited, but the potential availability impact warrants timely inventory, vendor review, and remediation planning for affected deployments.
Technical view
The issue is classified as CWE-16 and described as exposure of a resource to the wrong control sphere. CVSS 3.1 is 6.8 with local attack vector, low complexity, no privileges, no user interaction, low integrity impact, and high availability impact.
Likely exposure
Organizations using Philips Clinical Collaboration Platform versions 12.2.1 and prior should assess exposure. The source bundle does not identify other affected Philips products or deployment prerequisites beyond the local attack vector in CVSS.
Exploitation context
The bundle does not cite active exploitation, and CISA KEV status is false. The CVSS vector indicates local access, not remote network exploitation, but no detailed exploit conditions are provided in the supplied sources.
Researcher notes
Evidence is limited to official CVE, CISA, and Philips references. Do not assume remote exploitability or a public exploit. Focus validation on version confirmation, configuration exposure, access control boundaries, and vendor-stated remediation status.
Mitigation direction
- Identify all Philips Clinical Collaboration Platform deployments and versions.
- Prioritize versions 12.2.1 and prior for vendor-guided remediation review.
- Check Philips and CISA advisory guidance before changing clinical systems.
- Restrict access to affected systems to authorized personnel pending vendor direction.
- Coordinate remediation with clinical operations and Philips support.
Validation and detection
- Confirm whether Philips Clinical Collaboration Platform is deployed.
- Verify the installed version against 12.2.1 and prior.
- Review access boundaries for resources exposed to unintended actors.
- Check whether Philips advisory actions have been completed.
- Document residual risk if remediation depends on vendor scheduling.
Public sources used
Generated from the cited source records. This long-tail analysis has not been individually reviewed by a named human.
Conservative CVE-to-ATT&CK context
These mappings and lookup hints may be relevant to the vulnerability behavior, CWE, affected product, or exposure path. Glexia-inferred context is not an official MITRE, ATT&CK, CWE, or CVE Program mapping.
ATT&CK lookup starting points
Use these exact CWE pages and searches to review the Glexia ATT&CK library from this CVE's weakness and description context.
CWE-16: Exact CWE lookup
Use the exact CWE identifier as the starting point before reviewing related ATT&CK behavior. Open the exact CWE lookup page first, then review the ATT&CK searches from that MITRE weakness context. This is a Glexia lookup hint, not an official ATT&CK mapping.
Open ATT&CK lookupCVE-2020-16247 mapping review
Open the CVE-to-ATT&CK bridge for reviewed, inferred, or future official mappings tied to this CVE.
Open ATT&CK lookup- Severity
- Medium
- CVSS
- 6.8 (3.1)
- Known Exploited
- No
- Published
Vector: CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:H
CNA and ADP enrichment extracted from CVE v5
These fields come from the CVE record and ADP containers, not from Glexia's Take. They preserve time-varying source decisions such as CISA SSVC, KEV status, CVSS metrics, and provider references.
CVSS vector scores
1 official scoreWe collect every scored CVSS vector available in the official CNA and ADP containers. When more than one version is present, the table keeps the source vectors side by side instead of collapsing them into the highest score.
CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:H2.54.2Primary CVE scoreVulnerability scoring details
Base CVSS 3.1 score
6.8MediumVector: CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:H
Source materials
- CVE List V5 sourceCVE List V5
- https://us-cert.cisa.gov/ics/advisories/icsma-20-261-01CVE reference · x_refsource_MISC
- https://www.philips.com/a-w/security/security-advisories/product-security-2020.html#2020_archiveCVE reference
Products and packages named in the record
CWE details
CWE links open Glexia weakness intelligence pages with official CWE context, developer remediation guidance, and related CVE mappings.